Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2
19 août 2020 09h00 HE
|
Sorrento Therapeutics, Inc.
IND filing today for STI-1499 (COVI-GUARD™) for hospitalized COVID-19 patients.The initial trial is expected to be followed by pivotal trials with a goal of potentially receiving an EUA (Emergency Use...